Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Fexofenadine tablet dosing
Fexofenadine dosing · 1 trial · 1 indication
To characterize the pharmacokinetics of fexofenadine by assessment of maximum plasma fexofenadine concentration.
To characterize the pharmacokinetics of fexofenadine by assessment of area under the plasma concentration time curve from zero to infinity
| Arm | Type | Description |
|---|---|---|
| osimertinib and fexofenadine | EXPERIMENTAL | Sequential treatments of fexofenadine alone followed by osimertinib + fexofenadine, followed by osimertinib alone, followed by osimertinib + fexofenadine |
| Name | Type | Description |
|---|---|---|
| Fexofenadine tablet dosing | DRUG | Fexofenadine (P-gp substrate) 120mg taken once daily on Days 1 in Treatment Period 1 and Day 1 and Day 39 in Treatment Period 2 |
| Osimertininb tablet dosing | DRUG | Osimertininb 80 mg taken once daily on Day 1 and Days 4 to 41 in Treatment Period 2 |
Inclusion Criteria: * Male or female, ≥18 years * Histological or cytological confirmation diagnosis of NSCLC * Radiological documentation of disease progression while receiving previous continuous treatment with an EGFR-TKI. * Confirmation that the tumour harbours an EGFR mutation known to be asso...
Top 20 of 90 competitors
Fexofenadine dosing refers to the administration of fexofenadine, an HRH1 antagonist small molecule. In this context, it was studied as a probe substrate to assess drug-drug interactions in patients with EGFR-mutant non-small cell lung cancer. It is also known as fexofenadine tablet dosing.
Fexofenadine dosing targets HRH1, the histamine H1 receptor, acting as an antagonist. This mechanism is well established for fexofenadine, and in the oncology setting it was used to evaluate transporter-mediated interactions.
Fexofenadine dosing is being developed by AstraZeneca PLC, ticker AZN. The company sponsored a Phase 1 trial to study the effect of osimertinib on fexofenadine blood levels in patients with EGFR-mutant non-small cell lung cancer.
Fexofenadine dosing is in Phase 1 clinical development. The only listed trial, NCT02908750, is a completed Phase 1 study. It is investigational and has not been approved for the oncology indication studied.
Fexofenadine dosing has been evaluated in one clinical trial: NCT02908750, titled "Study to Assess the Effect of Osimertinib (TAGRISSO™) on Blood Levels of Fexofenadine in Patients With EGFRm+ NSCLC." This Phase 1 trial was completed and enrolled 24 patients across France, South Korea, and Spain.
Yes, Fexofenadine dosing is also known as fexofenadine tablet dosing. Both terms refer to the same HRH1 antagonist small molecule developed by AstraZeneca PLC for study in non-small cell lung cancer.